Natco Pharma Limited (NSE: NATCO PHARM) announces FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Lupin Limited (LUPIN) shares positive Phase 1 data on LNP8701, a novel SOS1 inhibitor, accepted for ASCO Annual Meeting 2026.
Sakar Healthcare Limited (SAKAR) records 42% YoY revenue growth in Q4 FY26, with EBITDA rising 67%.